Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer

by T.S. Uldrick, M.A. ‘Mac’ Cheever, P.H. Gonçalves, S. Fling, K. Aleman, B. Emu, M.S. Ernstoff, R. Gorelick, J. Kaiser, H. E Kohrt, A. Lacroix, M. Lindsley, L. M Lundgren, K. Lurain, F. Maldarelli, C. Parsons, E. Sharon, A. Widell, R. Yarchoan
Published 2017-12-01

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

by I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra, M. E. Suarez-Almazor, Y. Wang, K. Wiley, H. L. Kaufman, M. S. Ernstoff, on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group
Published 2017-11-01